Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Luseogliflozin on Risk of Ketoacidosis and Insulin Resistance in Type 2 Diabetes Mellitus Patients on Moderate Dose Insulin

NCT07876258 is registered in ClinicalTrials.gov with Aimi Fadilah Mohamad as lead sponsor.

NCT NCT07876258
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07876258 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Luseogliflozin on Risk of Ketoacidosis and Insulin Resistance in Type 2 Diabetes Mellitus Patients on Moderate Dose Insulin
Lead sponsor
Aimi Fadilah Mohamad
Phase
Phase 3
Overall status
Completed
Start date
May 1, 2022
Completion date
November 30, 2024
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus type 2